Pith. sign in

REVIEW 7 cited by

PharmAgents: Building a Virtual Pharma with Large Language Model Agents

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2503.22164 v2 pith:YYDB426I submitted 2025-03-28 q-bio.BM cs.AI

classification q-bio.BMcs.AI
keywords drugdiscoverypharmagentsagentscollaborationexplainablefuturelanguage
verification ladder T0 review T1 audit T2 compute T3 formal
0 comments
read the original abstract

The discovery of novel small molecule drugs remains a critical scientific challenge with far-reaching implications for treating diseases and advancing human health. Traditional drug development--especially for small molecule therapeutics--is a highly complex, resource-intensive, and time-consuming process that requires multidisciplinary collaboration. Recent breakthroughs in artificial intelligence (AI), particularly the rise of large language models (LLMs), present a transformative opportunity to streamline and accelerate this process. In this paper, we introduce PharmAgents, a virtual pharmaceutical ecosystem driven by LLM-based multi-agent collaboration. PharmAgents simulates the full drug discovery workflow--from target discovery to preclinical evaluation--by integrating explainable, LLM-driven agents equipped with specialized machine learning models and computational tools. Through structured knowledge exchange and automated optimization, PharmAgents identifies potential therapeutic targets, discovers promising lead compounds, enhances binding affinity and key molecular properties, and performs in silico analyses of toxicity and synthetic feasibility. Additionally, the system supports interpretability, agent interaction, and self-evolvement, enabling it to refine future drug designs based on prior experience. By showcasing the potential of LLM-powered multi-agent systems in drug discovery, this work establishes a new paradigm for autonomous, explainable, and scalable pharmaceutical research, with future extensions toward comprehensive drug lifecycle management.

Discussion (0). Sign in to comment.

Forward citations

Cited by 7 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. MolLingo: Molecule-Native Representations for LLM-Powered Scientific Agents

    cs.AI 2026-05 unverdicted novelty 7.0 of 10

    MolLingo introduces a multi-agent framework with BFE molecular representation and docking-grounded reasoning to outperform frontier LLMs on molecular design benchmarks including fourfold docking score gains.

  2. Camyla: Scaling Autonomous Research in Medical Image Segmentation

    cs.AI 2026-04 unverdicted novelty 7.0 of 10

    Camyla autonomously generates research proposals, experiments, and manuscripts in medical image segmentation, outperforming baselines on 24 of 31 recent datasets while producing 40 human-reviewed papers.

  3. Mol-Debate: Multi-Agent Debate Improves Structural Reasoning in Molecular Design

    cs.AI 2026-04 unverdicted novelty 6.0 of 10

    Mol-Debate applies multi-agent debate in an iterative loop with perspective orchestration to achieve state-of-the-art text-guided molecular design, scoring 59.82% exact match on ChEBI-20 and 50.52% weighted success on...

  4. Evaluating Agentic Bioinformatics through Function, Evidence, and Validation

    cs.AI 2026-07 conditional novelty 5.0 of 10

    Agentic bioinformatics systems mostly demonstrate planning and tool execution but rarely prospective empirical validation, so the paper argues evaluation should center on inspectable workflow trajectories (FEV) rather...

  5. Beyond SMILES: Evaluating Agentic Systems for Drug Discovery

    q-bio.QM 2026-02 conditional novelty 5.0 of 10

    Drug-discovery AI agents are built for small-molecule, big-pharma settings and lack peptide, in vivo, training-loop, small-lab, and multi-objective capabilities, even though LLMs themselves can reason about peptides.

  6. An Auditable Agent Platform For Automated Molecular Optimisation

    cs.LG 2025-08 conditional novelty 5.0 of 10

    A hierarchical multi-agent LLM platform with recorded provenance improved average predicted binding affinity for AKT1 by 31%, while single-agent runs favored drug-likeness.

  7. Agents in the Wild: Where Research Meets Deployment

    cs.AI 2026-07 unverdicted

    A tutorial description reviewing the state of LLM agent deployment, with no new research findings.

Pith tools